Loeb Partners Corp’s Medifast MED Stock Holding History

Loeb Partners Corp’s Portfolio MED Stock Details MED Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q1	–	Sell	-200	Closed	-$25K	–	224
2018 Q4	$25K	Buy	+200	New	+$34.2K	0.01%	196

Other funds holding MED

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JIM

Jupiter Investment Management London, United Kingdom $6.26B AUM 13.19% 1-Year Est. Return

HCM

Hoplite Capital Management New York $15.1M AUM 27.41% 1-Year Est. Return

Principal Financial Group Des Moines, Iowa $187B AUM 18.48% 1-Year Est. Return

HRCM

Hood River Capital Management Palm Beach Gardens, Florida $9.98B AUM 145.42% 1-Year Est. Return

Loeb Partners Corp's MED Position: Q1 2019 in Review

Loeb Partners Corp sold out of Medifast (MED) in Q1 2019, closing a stake of 200 shares — an estimated $25K sold.

Loeb Partners Corp first reported a position in MED in Q4 2018 and held it in 1 quarter. The position peaked at $25K in Q4 2018. 246 funds tracked by Wall St. Rank hold MED as of Q1 2019.

Loeb Partners Corp reported no remaining Medifast position as of Q1 2019 after selling out during the quarter.
Loeb Partners Corp sold 200 Medifast shares in Q1 2019, an estimated $25K.
Loeb Partners Corp first reported a position in Medifast in Q4 2018 and held it in 1 quarter.
Loeb Partners Corp's Medifast position peaked at $25K in Q4 2018.
246 funds tracked by Wall St. Rank held Medifast as of Q1 2019.

Based on Loeb Partners Corp's 13F filing for Q1 2019, filed 14 May 2019.